First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

被引：3
|
作者：
Hafner, Susanne [1 ]
机构：
[1] Ulm Univ, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2021年 / 6卷 / 01期
关键词：
CELL LUNG-CANCER; BEVACIZUMAB; ERLOTINIB; MULTICENTER;
D O I：
10.1038/s41392-021-00813-y
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC
    Stock-Martineau, Sophie
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1793 - 1797
  • [32] Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
    Cortot, Alexis B.
    Moro-Sibilot, Denis
    Cadranel, Jacques
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1827 - 1827
  • [33] The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC
    Chen, D.
    Chu, T.
    Chang, Q.
    Zhang, Y.
    Xiong, L.
    Qiao, R.
    Teng, J.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S937 - S937
  • [34] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [35] Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Sugiyama, T.
    Minemura, H.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Kaburagi, T.
    Minato, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S908 - S908
  • [36] Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
    Sabari, J. K.
    Yu, H. A.
    Mahadevia, P.
    Liu, Y.
    Demirdjian, L.
    Sultan, A. A.
    Chen, Y. H.
    Wang, X.
    Passaro, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S620
  • [37] The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Chin, Chun-Shih
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 434 - 444
  • [38] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [39] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
  • [40] Prognosis of EGFR-mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line EGFR-TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study
    Kashiwabara, Kosuke
    Fuji, Shinji
    Tsumura, Shinsuke
    Sakamoto, Kazuhiko
    ANTICANCER RESEARCH, 2020, 40 (02) : 1117 - 1121
12345